AstraZeneca
Pays vs peer median
×1.05
+5% premium
Sample
47
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.11 | 33 |
| immunology | ×0.73 | 3 |
| rareDisease | ×0.70 | 3 |
| cardiovascular | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.43 | 15 |
| phase 1 | ×0.88 | 12 |
| phase 3 | ×1.32 | 7 |
| preclinical | ×0.89 | 5 |
| phase 2 | ×1.12 | 4 |
| discovery | ×0.70 | 4 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | SYH2082 | CSPC Pharmaceutical | obesity | preclinical | $1.2B | $18.5B |
| 2026 | — | CSPC Pharmaceutical Group | obesity and diabetes | preclinical | $1.2B | $18.5B |
| 2025 | Anti-BRAF V600E-001 | Karyopharm Therapeutics | Sarcoma | phase_2 | $320M | $1.7B |
| 2025 | Anti-MEK-001 | Immatics | T-cell Lymphoma | phase_1 | $253M | $2.9B |
| 2025 | KIT-mab | MorphoSys | Breast (TNBC) | approved | $2.8B | $8.8B |
| 2025 | KRAS G12C-tinib | Celldex Therapeutics | Endometrial | phase_1 | $104M | $1.0B |
| 2025 | ALK-201 | Intellia Therapeutics | Head & Neck | discovery | $20M | $363M |
| 2025 | SHP2-mab | Umoja Biopharma | Bladder | preclinical | $59M | $414M |
| 2024 | JAK-101 | Replimune | Melanoma | phase_3 | $853M | $7.2B |
| 2024 | breast | Astellia Oncology | breast | phase_1 | $100M | $425M |
| 2024 | egfr_solid_tumors | Pinetree Therapeutics | egfr_solid_tumors | preclinical | $50M | $500M |
| 2024 | autoimmune | Numab Therapeutics | autoimmune | phase_1 | $50M | $1.2B |
| 2024 | WEE1 | Deciphera Pharmaceuticals | Ovarian | phase_2 | $470M | $3.2B |
| 2024 | PD-L1-tinib | TCR2 Therapeutics | Sarcoma | phase_2 | $157M | $1.3B |
| 2024 | prostate | Convergent Therapeutics | prostate | phase_1 | $100M | $1.8B |
How this is computed
For each AstraZeneca deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 47 disclosed deal premiums vs. peer medians. Raw premium 1.047, clamped to [0.7, 1.5].